Aptamer Group plc (APTA) ORD GBP0.0001

Sell:0.80pBuy:0.85p0.03p (3.12%)

Prices delayed by at least 15 minutes
Sell:0.80p
Buy:0.85p
Change:0.03p (3.12%)
Prices delayed by at least 15 minutes
Sell:0.80p
Buy:0.85p
Change:0.03p (3.12%)
Prices delayed by at least 15 minutes

Company Information

About this company

Aptamer Group plc is a United Kingdom-based global developer of aptamer-based ligands. The Company develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA).

Key people

Arron C. Tolley
Chief Executive Officer, Executive Director
Andrew Rapson
Chief Financial Officer, Secretary
David H. Bunka
Chief Scientific Officer, Executive Director
Adam Hargreaves
Independent Non-Executive Chairman of the Board
Tim Sykes
Independent Non-Executive Director
Click to see more

Key facts

  • Shares in issue
    2.70bn
  • EPIC
    APTA
  • ISIN
    GB00BNRRP542
  • Location
    United Kingdom
  • Sector
    Technology
  • Industry
    Software & Programming
  • Market cap
    £22.25m
  • Employees
    31
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.